Lipidor AB has announced a significant milestone in its Phase III clinical trial evaluating AKP02G2 for the treatment of mild to moderate psoriasis. As of January 21, 2025, half of the 294 patients required for the study have been randomized. The trial is designed to compare the therapeutic effect of AKP02G2 with that of a market-leading product for psoriasis.
The Phase III study is being conducted by a Clinical Research Organisation (CRO) with extensive experience in dermatological research. Patient recruitment began in September 2024, with 15 clinics now actively participating.
According to Lipidor, the winter season and the increased number of recruiting clinics have accelerated patient recruitment. The company anticipates completing patient recruitment in February, with topline results expected in April 2025.
Management Commentary
"The fact that half of the patients have now been recruited to the study is an incredibly important milestone," said Ola Holmlund, CEO of Lipidor. "The start-up of the clinics is a critical phase and now all clinics are active, which creates a good momentum. We are aiming for a fully recruited study according to the forecast communicated by the company's CRO."
Lipidor intends to announce when all patients have been enrolled in the study. AKP02G2 represents a key asset in Lipidor's pipeline of pharmaceutical development projects focused on topical treatments for skin diseases.
